RPID earnings analysis
What we found in RPID's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Rapid Micro Biosystems reported Q1 2026 results with revenue of $8.0 million, surpassing estimates and marking an 11.1% increase year-over-year. However, the company reported an EPS loss of -$0.31, missing expectations due to rising operating losses and expenses.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth Exceeds Estimates
- Revenue reached $8.0 million, exceeding the estimated $7.58 million and showing an 11.1% increase from $7.2 million in Q1 2025.
- Product Revenue Surge
- Product revenue increased by $1.5 million, or 36.0%, driven by higher system placements and consumable shipments.
- Recurring Revenue Improvement
- Recurring revenue grew 27.7% to $5.1 million, constituting 63.3% of total revenue, up from 55.1% in Q1 2025.
- Positive Gross Margin Trend Continues
- Gross margin improved to 4.6% for Q1 2026, up from 3.1% in Q4 2025.
- Strong Capital Structure
- Cash and cash equivalents as of March 31, 2026, stood at $13.8 million, with total assets of $23.2 million.
- Long-Term Growth Outlook Reaffirmed
- The company reiterated full-year 2026 revenue guidance of $37 million to $41 million, with an expected gross margin around 20%.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Increased Operating Losses
- Net loss rose to $14.3 million in Q1 2026, compared to $11.3 million in Q1 2025, driven by higher operational costs.
- Cash Flow Concerns
- Operating cash flows worsened with net cash used at $15.1 million, increasing from $9.1 million in Q1 2025.
- Debt Servicing Under Pressure
- Interest expense jumped to $639,000 from $12,000 in the previous year due to new long-term debt incurred.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.31
- Gross margin
- 4.6%
- Segment
- Product revenue $5,578M, Service revenue $2,424M
What they said about what is next.
Maintains revenue guidance of $37M-$41M for 2026; strong outlook pending ongoing growth in product placements.
The filing reads about the same as the one before it.
What came before.
- 10-K · March 12, 2026
- Rapid Micro Biosystems’ 2025 10-K emphasizes commercialization of its Growth Direct MQC platform (190 systems placed; ~9 million consumables sold) and reports continued revenue growth (sum of 2025 quarters = $33.0M vs…
- 10-Q · November 7, 2025
- Rapid Micro Biosystems reported Q3 revenue of $7,838,000, up from $7,604,000 in Q3 2024, with gross margin improving to ~8.9% and a slightly narrower operating loss of $(11,372,000) vs $(12,039,000) a year earlier.…
- 10-Q · August 12, 2025
- Rapid Micro Biosystems reported Q2 2025 revenue of $7,262,000, up 9.7% year-over-year and modestly (+$57,000) versus Q1 2025. Gross profit was $275,000 (3.8% margin) but operating loss remained large at $(12,148,000),…
- 10-Q · May 9, 2025
- Rapid Micro Biosystems reported Q1 revenue of $7,205,000 (vs $5,611,000 in Q1 2024), driving year-over-year revenue growth and a swing to a positive gross margin of 5.6%. Operating loss narrowed to $(11,661,000) and…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing RPID makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever